Lysophosphatidic acid-induced vascular neointimal formation in mouse carotid arteries is mediated by the matricellular protein CCN1/Cyr61
Authors:
- 1 December 2016
- journal article
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 311 (6) , C975-C984
Abstract
Vascular smooth muscle cell (SMC) migration is an essential step involved in neointimal formation in restenosis and atherosclerosis. Lysophosphatidic acid (LPA) is a bioactive component of oxidized low-density lipoprotein and is produced by activated platelets, implying that LPA influences vascular remodeling. Our previous study revealed that matricellular protein CCN1, a prominent extracellular matrix (ECM) protein, mediates LPA-induced SMC migration in vitro. Here we examined the role of CCN1 in LPA-induced neointimal formation. By using LPA infusion of carotid artery in a mouse model, we demonstrated that LPA highly induced CCN1 expression (approximately six- to sevenfold) in neointimal lesions. Downregulation of CCN1 expression with the specific CCN1 siRNA in carotid arteries blocked LPA-induced neointimal formation, indicating that CCN1 is essential in LPA-induced neointimal formation. We then used LPA receptor knockout (LPA1−/−, LPA2−/−, and LPA3−/−) mice to examine LPA receptor function in CCN1 expression in vivo and in LPA-induced neointimal formation. Our data reveal that LPA1 deficiency, but not LPA2 or LPA3 deficiency, prevents LPA-induced CCN1 expression in vivo in mouse carotid arteries. We also observed that LPA1 deficiency blunted LPA infusion-induced neointimal formation, indicating that LPA1 is the major mediator for LPA-induced vascular remodeling. Our in vivo model of LPA-induced neointimal formation established a key role of the ECM protein CCN1 in mediating LPA-induced neointimal formation. Our data support the notion that the LPA1-CCN1 axis may be the central control for SMC migration and vascular remodeling. CCN1 may serve as an important vascular disease marker and potential target for vascular therapeutic intervention.Keywords
Funding Information
- HHS | National Institutes of Health (NIH) (HL107466, AG026640)
- University of Tennessee (UT) (COE grant)
This publication has 58 references indexed in Scilit:
- CCN1/CYR61: the very model of a modern matricellular proteinCellular and Molecular Life Sciences, 2011
- International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor NomenclaturePharmacological Reviews, 2010
- Short-Term Stimulation of Calcium-Permeable Transient Receptor Potential Canonical 5–Containing Channels by Oxidized PhospholipidsArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Loss of Insulin Signaling in Vascular Endothelial Cells Accelerates Atherosclerosis in Apolipoprotein E Null MiceCell Metabolism, 2010
- LPA Receptors: Subtypes and Biological ActionsAnnual Review of Pharmacology and Toxicology, 2010
- Lysophosphatidic acid-induced arterial wall remodeling: Requirement of PPARγ but not LPA1 or LPA2 GPCRCellular Signalling, 2009
- Oxidized Phospholipids Induce Type VIII Collagen Expression and Vascular Smooth Muscle Cell MigrationCirculation Research, 2009
- Lysophosphatidic Acid Receptors 1 and 2 Play Roles in Regulation of Vascular Injury Responses but Not Blood PressureCirculation Research, 2008
- Role of Smooth Muscle Cells in the Initiation and Early Progression of AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- The pathogenesis of atherosclerosis: a perspective for the 1990sNature, 1993